Actinogen Medical (ACW)
20mins delayed
Movement
1 Year Return
Actinogen Medical Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $33.49 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
The BIGGEST ASX
Spreadsheet yet!
Download in Excel or PDF for printing
Data on 1,800+ ASX Companies
12-month Price Targets
EPS & Dividends
52w Highs & Lows
It's FREE until 29 February
ACW Statistics
21 February
1,245 / 2,267
ASX Size Rank
1yr Return
vs Sector (1yr)
-108.79%
vs ASX 200 (1yr)
-60.73%
$33.49 million
Market Cap
Share Issue
1.12 billion
All Ords (%)
N/A
Short Sold
0.02%
Current Fundamentals
21 February
N/A
PE Ratio
EPS ($)
-0.009
Earnings Yield
-30.00%
NTA ($)
0.01
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Actinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.
Former Names
Actinogen Limited (ACW), 17/11/2015
Upcoming Calendar
| 14 Aug 2020 | Report (Annual) |
| 14 Aug 2020 | Report (Prelim) |
| 20 Oct 2020 | Report (Annual) |
| 18 Feb 2021 | Report (Interim) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
ACW is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Dr George Morstyn | Non-Executive Director | Dec 2017 |
|
| Mr Malcolm John McComas | Non-Executive Director | Apr 2019 |
|
| Dr Geoffrey E.D Brooke | Non-Executive Chairman, Non-Executive Director | Mar 2017 |
|
| Dr John (Bill) William Ketelbey | Chief Executive Officer, Managing Director | Dec 2014 |
|
Director Transactions
ACW directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 31/01/20 | John (Bill) Ketelbey | Cancelled | 3,000,000 | $0.035 | $105,000 | Cancellation of securities. |
| 22/11/19 | John (Bill) Ketelbey | Transfer | 9,000,000 | $0.050 | $450,000 | As advised by the company. |
| 12/04/19 | Malcolm McComas | Issued | 3,000,000 | $0.052 | $156,000 | Issue of options. |
| 13/12/18 | George Morstyn | Issued | 1,500,000 | $0.048 | $72,000 | Issue of options. |
| 13/12/18 | Geoffrey Brooke | Issued | 4,900,000 | $0.048 | $235,200 | Issue of options. |
| 13/12/18 | John (Bill) Ketelbey | Issued | 11,700,000 | $0.048 | $561,600 | Issue of options. |
| 13/07/18 | Geoffrey Brooke | Issued | 300,000 | $0.050 | $15,000 | Participation in share purchase plan. |
| 13/07/18 | John (Bill) Ketelbey | Issued | 300,000 | $0.050 | $15,000 | Participation in share purchase plan. |
| 01/06/18 | George Morstyn | Buy | +200,000 | $0.051 | $10,282 | On-market trade. |
| 22/01/18 | Geoffrey Brooke | Issued | 625,000 | $0.040 | $25,000 | Placement. |
| 22/01/18 | Geoffrey Brooke | Issued | 312,500 | $0.041 | $12,812 | Placement. |
| 21/12/17 | Geoffrey Brooke | Issued | 53,333 | $0.044 | $2,346 | Issue of options. |
| 21/12/17 | Jason Loveridge | Issued | 3,716,677 | $0.044 | $163,533 | Issue of options. |
| 21/12/17 | John (Bill) Ketelbey | Issued | 1,647,172 | $0.044 | $72,475 | Issue of options. |
| 06/07/17 | Anton Uvarov | Transfer | 187,244 | $0.061 | $11,473 | Off-market transfer. |
| 29/03/17 | Geoffrey Brooke | Buy | +400,000 | $0.066 | $26,521 | On-market trade. |
| 24/03/17 | Geoffrey Brooke | Issued | 5,000,000 | $0.060 | $300,000 | Issue of securities. |
| 24/12/15 | John (Bill) Ketelbey | Buy | +10,909 | $0.058 | $629 | |
| 20/05/15 | John (Bill) Ketelbey | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Jason Loveridge | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Anton Uvarov | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Martin Rogers | Issued | 157,894 | $0.095 | $15,000 | |
| 01/12/14 | Anton Uvarov | Buy | +2,000,000 | $0.020 | $40,000 | |
| 01/12/14 | Brendan de Kauwe | Buy | +2,500,000 | $0.020 | $50,000 | |
| 12/12/13 | Daniel Parasiliti | Issued | 1,000,000 | $0.010 | $10,000 | |
| 12/12/13 | Brendan De Kauwe | Issued | 2,000,000 | $0.010 | $20,000 | |
| 09/07/13 | Zhukov (Zeke) Pervan | Buy | +66,666 | $0.021 | $1,381 | |
| 02/07/13 | Zhukov (Zeke) Pervan | Transfer | 9,333 | $1.000 | $9,333 | |
| 02/07/13 | Zhukov (Zeke) Pervan | Transfer | 933,334 | $0.010 | $9,333 | |
| 19/06/13 | Zhukov (Zeke) Pervan | Transfer | 5,666,666 | $0.019 | $107,666 | |
| 19/06/13 | David Zohar | Buy | +221,830 | $0.019 | $4,214 | |
| 08/04/13 | David Zohar | Buy | +142,017 | $0.023 | $3,266 | |
| 02/04/13 | David Zohar | Buy | +20,000 | $0.022 | $440 | |
| 02/04/13 | David Zohar | Expiry | 11,750,000 | $0.021 | $246,750 |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 48 | 88 | 268 | 1,473 | 932 | 2,809 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 226,324,149 | 20.22% |
| Edinburgh Technology Fund Limited | 48,147,864 | 4.30% |
| Tisia Nominees Pty Ltd |
29,867,184 | 2.67% |
| Mrs Sarah Cameron | 25,174,137 | 2.25% |
| Mr Ross Edward Gustafson |
22,877,572 | 2.04% |
| Jinark Pty Ltd |
20,360,843 | 1.82% |
| Bannaby Investments Pty Limited |
17,976,761 | 1.61% |
| Sunset Capital Management Pty Ltd |
15,392,421 | 1.38% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd DRP | 14,302,319 | 1.28% |
| Comsec Nominees Pty Limited | 12,891,130 | 1.15% |
| Dr John William Ketelbey | 12,157,894 | 1.09% |
| Brazil Farming Pty Ltd | 11,000,000 | 0.98% |
| Mr Steven Veronese | 10,008,001 | 0.89% |
| Oaktone Nominees Pty Ltd |
10,000,000 | 0.89% |
| Tets Pty Ltd | 10,000,000 | 0.89% |
| Citicorp Nominees Pty Limited | 8,869,221 | 0.79% |
| Griffin & Grace Investments Pty Ltd |
8,500,000 | 0.76% |
| Romfal Sifat Pty Ltd |
8,000,000 | 0.71% |
| Mr Alan Giles Sauran | 7,600,000 | 0.68% |
| BNP Parabis Nominees Pty Ltd |
7,560,729 | 0.68% |
| All other shareholders | 52.92 % | |
The Top 20 Shareholders of ACW hold 47.08% of shares on issue.
ACW Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
ACW Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2018 | $0.048 | 29 June |
| 2017 | $0.061 | 28 June |
| 2016 | $0.072 | 28 June |
| 2015 | $0.072 | 30 June |
| 2014 | $0.011 | 30 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.
Incorporated: Actinogen Limited was incorporated on 26/03/1999 in Western Australia.
Suite 901, Level 9, 109 Pitt St
Sydney NSW 2000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.